 Keros Therapeutics, Inc. Keros KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that four abstracts will be presented from the KER-050 and ALK2 hematology programs, including topline data from the Phase 1 clinical trial of KER-050, at the 25th Annual Congress of the European Hematology Association EHA, to be held as a virtual event from June 11-14, 2020. We are pleased to be given the opportunity to present at this years virtual Congress, said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. 